ERBB2 and neoplasm: Excluding the studies conducted in search of tumor markers, there are several studies that evaluate the potential therapeutic use of the monoclonal antibody trastuzumab and EGFR-HER2 inhibitor lapatinip in bladder cancer (15, 21).